.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 9,352,025

« Back to Dashboard

Details for Patent: 9,352,025

Title:Combination of dopamine agonists plus first phase insulin secretagogues for the treatment of metabolic disorders
Abstract: The present invention is directed to a method of treating a metabolic disorder or key elements of a metabolic disorder such method comprising the use of an agent(s) that increases central dopaminergic activity plus a first-phase insulin secretagouge.
Inventor(s): Cincotta; Anthony H. (Tiverton, RI)
Assignee: VeroScience LLC (Tiverton, RI)
Filing Date:Oct 03, 2014
Application Number:14/506,353
Claims:1. A method of treating a metabolic disorder or key elements of a metabolic disorder such method comprising the step of administering to a patient having a metabolic disorder or a patient in need thereof, (a) a dopamine receptor agonist; and (b) a first-phase insulin secretagogue selected from the group consisting of glucagon like peptide-1 (GLP-1) or an analog thereof, a dipeptidyl peptidase inhibitor, gastric inhibitory polypeptide (also known as glucose-dependent insulinotropic peptide), a meglitinide, repaglinide, nataglinide and short acting insulin, wherein the dosage of each of said dopamine receptor agonist and first-phase insulin secretagogue in combination, provides a therapeutic effect greater than the additive effect of administering the same dosage of each of said dopamine receptor agonist and first-phase insulin secretagogue alone and wherein the dopamine receptor agonist is administered so as to increase central dopaminergic activity at the time of day its circadian rhythm naturally peaks in healthy subjects of the same species and said first phase insulin secretagogue is administered such that an effective amount is present daily.

2. The method of claim 1, wherein the dopamine receptor agonist is selected from the group consisting of bromocriptine, lisuride, hydergene, dihydroergotoxine, and other dopamine D2 receptor agonists with low or no serotonin 2B receptor agonist activity.

3. The method of claim wherein metabolic disorder is selected from the group consisting of pre-diabetes, Impaired Fasting Glucose, Impaired Glucose Tolerance and Type 2 diabetes.

4. The method of claim wherein the metabolic disorder is selected from the group consisting of the metabolic syndrome, Type 2 diabetes, obesity, prediabetes, insulin resistance, hyperinsulinemia, cardiovascular disease, elevated plasma norepinephrine, elevated cardiovascular-related inflammatory factors or potentiators of vascular endothelial dysfunction, hyperlipoproteinemia, atherosclerosis, hyperphagia, hyperglycemia, hyperlipidemia, hypertension, and high blood pressure.

5. The method of claim wherein the key elements of metabolic disorders are selected from the group consisting of impaired fasting glucose, impaired glucose tolerance, increased waist circumference, increased visceral fat content, increased fasting plasma glucose, increased fasting plasma triglycerides, increased fasting plasma free fatty acids, decreased fasting plasma high density lipoprotein level, increased systolic or diastolic blood pressure, increased plasma postprandial triglyceride or free fatty acid levels, increased cellular oxidative stress or plasma indicators thereof, increased circulating hypercoagulative state, arteriosclerosis, coronary artery disease, peripheral vascular disease, congestive heart failure, hepatic steatosis, renal disease including renal insufficiency, and cerebrovascular disease.

6. The method of claim wherein said dopamine receptor agonist is administered to a human to increase central dopaminergic activity primarily within 4 hours of waking in the morning.

7. The method of claim wherein said dopamine receptor agonist is administered within 2 hours of waking in the morning.

8. The method of claim 1, wherein the dosage of the dopamine receptor agonist is insufficient to effectively treat said disorder or key elements of said disorder without co-administration of the first-phase insulin secretagogue.

9. The method of claim 1, wherein the dosage of the first-phase insulin secretagogue is insufficient to effectively treat said disorder or key elements of said disorder without co-administration of the dopamine receptor agonist.

10. The method of claim 1, wherein the dosage of each of the dopamine receptor agonist and the first-phase insulin secretagogue in combination are effective to treat said disorder or key elements of said disorder.

11. The method of claim 1, wherein the dopamine receptor agonist is selected from the group consisting of quinpirole, quinerolane, talipexole, ropinirole, apomorphine, terguride, fenoldopam, dihydroergocryptine and combinations thereof.

12. The method of claim wherein the dosage of said first-phase insulin secretagogue effective to treat said disorder when administered with said dopamine receptor agonist is less than the dosage of said secretagogue effective to treat said disorder when administered without said dopamine receptor agonist.

13. The method of claim 1, wherein the dopamine receptor agonist is a combination of a dopamine D1 receptor agonist and a dopamine D2 receptor agonist.

14. A method of treating glucose intolerance or insulin resistance in a mammal in need of such treatment, such method comprising: administering to a mammal suffering from glucose intolerance (a) a dopamine D2 receptor agonist selected from the group consisting of bromocriptine, lisuride, hydergene, dihydroergotoxine, and other dopamine D2 receptor agonists with low or no serotonin 2B receptor agonist activity; and (b) a first-phase insulin secretagogue selected from the group consisting of glucagon like peptide-1 (GLP-1) or an analog thereof, a dipeptidyl peptidase inhibitor, gastric inhibitory polypeptide (also known as glucose-dependent insulinotropic peptide), a meglitinide, repaglinide, nataglinide and short acting insulin, wherein the dosage of each of said dopamine D2 receptor agonist and first-phase insulin secretagogue in combination provides a therapeutic effect greater than the additive effect of administering the same dosage of each of said dopamine D2 receptor agonist and first-phase insulin secretagogue alone and wherein the dopamine receptor agonist is administered so as to increase central dopaminergic activity at the time of day its circadian rhythm naturally peaks in healthy subjects of the same species and said first phase insulin secretagogue is administered such that an effective amount is present daily.

15. The method of claim 14, wherein the mammal suffers from diabetes or pre-diabetes.

16. A method of treating glucose intolerance or insulin resistance in a mammal in need of such treatment, such method comprising: administering to a mammal suffering from glucose intolerance or insulin resistance (a) bromocriptine or a pharmaceutically acceptable salt thereof; and (b) a first-phase insulin secretagogue selected from the group consisting of GLP-1 or an analog thereof and insulin, wherein the dosage of each of bromocryptine or a pharmaceutically acceptable salt thereof and first-phase insulin secretagogue in combination, provides a therapeutic effect greater than the additive effect of administering the same dosage of each of said bromocriptine or a pharmaceutically acceptable salt thereof and said first-phase insulin secretagogue alone and wherein the bromocryptine or a pharmaceutically acceptable salt thereof is administered to increase central dopaminergic activity at the time of day its circadian rhythm naturally peaks in healthy subjects of the same species and said first phase insulin secretagogue is administered such that an effective amount is present daily.

17. The method of claim 16, wherein the salt is mesylate.

18. The method of claim 16, wherein the mammal is suffering from type 2 diabetes.

19. A method of treating a metabolic disorder or key elements of a metabolic disorder such method comprising the step of administering to a patient having a metabolic disorder or a patient in need thereof, (a) a dopamine receptor agonist; and (b) a first-phase insulin secretagogue selected from the group consisting of glucagon like peptide-1 (GLP-1) or an analog thereof, a dipeptidyl peptidase inhibitor, gastric inhibitory polypeptide (also known as glucose-dependent insulinotropic peptide), a meglitinide, repaglinide, nataglinide and short acting insulin, wherein the dosage of each of said dopamine receptor agonist and first-phase insulin in combination, provides a therapeutic effect greater than the additive effect of administering the same dosage of each of said dopamine receptor agonist and first-phase insulin secretagogue alone and wherein said dopamine receptor agonist and said first phase insulin secretagogue are administered such that an effective amount of each is present daily.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc